Abstract
Background: Neuropathic pain (NeP) is a distinct type of pain caused by damage to the nervous system itself. This often severe and chronic type of pain requires specific treatments that target the underlying pain pathophysiology.
Aim: The purpose of the current narrative review is to provide an overview of pregabalin (Lyrica1) for the treatment of NeP including its effects on pain, pain-related sleep interference, and other health-related outcomes, timing of therapeutic effect, safety and tolerability, and dosing. The information provided here will help primary care providers develop more effective NeP treatment strategies.
Note
Transparency
Declaration of funding
Development of this manuscript was sponsored by Pfizer Inc.
Author contributions: All authors were involved in the preparation and review of this manuscript, and all approved its final submission to the journal.
Declaration of financial/other relationships
Y.D. has disclosed that she serves or has recently served as a consultant to Pfizer, Depomed, Charleston Labs, AstraZeneca, and Ortho‐McNeil; acted as part of a speaker’s bureau for Purdue; receives book royalties from Springer Publishing; serves as a peer reviewer for Elsevier and Lippincott; and serves on the editorial boards for Nursing and The Nurse Practitioner Journal. B.M. has disclosed that he serves or has recently served as a consultant to Pfizer, Collegium, Millennium, Takeda, Depomed, Janssen, Kaléo, and AstraZeneca; and owns stock in Johnson & Johnson, Protein Design Labs, BioSpecifics Technologies, Nektar Therapeutics, Galena, and Collegium. B.P., R.B., and A.T. have disclosed that they are all full-time employees of, and own stock in, Pfizer. A.A. has disclosed that she was a full-time employee of Pfizer during the development and submission of this manuscript.
CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Acknowledgments
Medical writing support was provided by Matt Soulsby PhD CMPP of Engage Scientific Solutions, and was funded by Pfizer Inc.
Notes
1 Lyrica is a registered trade name of Pfizer Inc, New York, NY